食道癌における血中cytokeratin19mRNAの存在とその臨床腫瘍学的意義

食管癌血液中细胞角蛋白19 mRNA的存在及其临床肿瘤学意义

• 批准号: 08770937
• 负责人: 竹島 薫
• 金额: $ 0.64万
• 依托单位: Keio University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Encouragement of Young Scientists (A)
• 财政年份: 1996
• 资助国家: 日本
• 起止时间: 1996 至 无数据
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-08770937/
• 关键词: 食道癌; cytokeratin19; 末梢血中癌細胞; mRNA; RT-PCR

上皮細胞に特異的な細胞内骨格であるcytokeratin19(CK19)mRUAに対するRT-PCR法を用いて血中食道癌細胞を鋭敏に同定する方法を開発し、血中食道癌細胞の存在とその臨床腫瘍学的特性との相関を検討した。1994年12月より1996年1月まで教室にて食道扁平上皮癌と診断された26縮症例を対象とした。CK19遺伝子構造から2組のprimer pairをDNA合成機にて合成し、末消血より遊廓細胞を分離しAGPC法、逆転写反応にてcDNAを作製した。基礎的検討としてヒト食道癌細胞株5株と、9名の健康成人末消血を用い、検出感度の検討にはTE8を正常末消血に混入した希釈系列を用いた。TNM分類はCT,EUSなどの画像診断法により決定し、血中食道癌細胞の存在とTNM分類との相関を検討した。本法の検出感度は血中有核細胞10^6個当たり食道癌細胞25個であり、健康成人末消血ではCK19mRNAは検出されなかった。全26症例中16例が評価可能であり、全16症例中CK19mRNA発現率はT2以下で22%、T3以上で71%で認め、発現率に有意の差を認めた。また、TNM分類でもその発現率はStageII B以下で20%、StageIIIいじょうで83%であり、発現率に有意差を認めた。StageII B以下の10例虫再発を来した1例およびStageIII以上の6症例中臓器転移を認めた2例はCK19mRNAが陽性であった。方法により食道癌患者末消血中に癌細胞が存在し、これらが腫瘍マーカーとして利用できることが示唆され、方法を利用すればsystemic diseaseとしての食道癌の悪性度をsubclinical stageで高感度診断できるし考えられた。

Epithelial cell-specific intracellular lattice cytokeratin19 (CK19) mRUA is used for RT-PCR method The sensitivity of esophageal cancer cells in the blood is the same as the determination method, and the presence of esophageal cancer cells in the blood is related to the characteristics of clinical oncology and its correlation. In December 1994, in January 1996, the diagnosis of esophageal squamous epithelial carcinoma was made in January 1996. There were 26 cases of schizophrenia. The CK19 gene was constructed using a 2-group primer pair DNA synthesizer, which was synthesized by a DNA synthesis machine, which was used to isolate cells using the AGPC method. The basic 検検検恫はTE8 normal esophageal cancer cell line 5 strains, 9 healthy adults with terminal hemorrhage were used. The TNM classification is determined by CT and EUS imaging diagnostic methods, and the presence of esophageal cancer cells in the blood is related to the TNM classification. The sensitivity of this method is that 10^6 nucleated cells in the blood can be compared with 25 esophageal cancer cells, and CK19mRNA can be detected in healthy adults without blood loss. Among the total 26 cases, 16 cases were not evaluated as possible. Among the total 16 cases, the occurrence rate of CK19mRNA was 22% for T2 and below, and 71% for T3 and above. The occurrence rate was not significant and was not confirmed. The occurrence rate of TNM classification is 20% for Stage II B and below, and the occurrence rate of Stage III is 83%, and the occurrence rate is intentionally different. Of the 10 cases below Stage II B, the disease has reappeared, and 1 case has been confirmed, and among the 6 cases above Stage III, the disease has been confirmed, and 2 cases have been confirmed to be CK19mRNA positive. Method: The presence of cancer cells in the terminal blood of patients with esophageal cancer. The method of using the system to show the presence of cancer cells. diseaseとしてのesophageal cancerの悪性degreeをsubclinical stageでhigh sensitivity diagnosisできるしtestえられた.